Open AccessPreclinical Appraisal of Hematinic Potential of Mandura Bhasma for Treating Anemia
Author(s) -
Deepak Khobragade,
Mrunali S. Potbhare,
Awdhut Pimpale,
Sagar B. Wankhede,
Chandrashekhar R. Tempe
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i30b31656
Subject(s) - hematinic , body weight , medicine , anemia , pharmacology , oral administration
Aims: To evaluate hematinic potential of mandura bhasma.
Study Design: Experimental study.
Place and Duration of Study: Institute of Pharmaceutical Education and Research, Wardha, Maharashtra, India. 6 Months.
Methodology: The anti-anaemic potential of Mandura bhasma in Wistar rats was investigated. Anaemia was induced in rats with phenyl hydrazine hydrochloride at a dose of 10 mg kg-1 body weight by oral administration. Anaemia was treated with mandura bhasma administered in three different doses based on body weight.
Results: In vivo investigation showed that though the dose of 6mg kg-1 body weight of mandura bhasm produced only a minimal antianaemic (hematinic) effect, oral daily dose of 11 mg kg-1 body weight and 22mg kg-1 body weight a produced a significant (P < 0.05) antianaemic effect when compared to standard drug ferrous sulphate indicating dose dependent activity.
Conclusions: The results indicate that Mandura Bhasm have very potential dose dependant hematinic activity and can be a safe and effective drug for treating anemia.